00.06.02ac Preventive Care Services (Independence)
Effective August 15, 2019, the purpose of this communication is to provide advance notice regarding updated preventive coverage positions for human papillomavirus (HPV) vaccine and serogroup B meningococcal (MenB) vaccine for individuals enrolled in the Company's Commercial Products.
Human Papillomavirus (HPV) Vaccine
Previously, Advisory Committee of Immunization Practices (ACIP) considered HPV vaccine preventive for individuals aged 9 through 26 years. On August 15, 2019, the ACIP updated their recommendation for HPV vaccine to expand age recommendation for vaccination. In addition to previous recommendations, ACIP also recommends HPV vaccine based on shared clinical decision making for individuals aged 27 through 45 years who are not adequately vaccinated.
Serogroup B Meningococcal (MenB) Vaccine
In June 2019, ACIP updated their recommendation of serogroup B meningococcal (MenB) vaccine to include recommendations for a booster for individuals at increased risk for serogroup B meningococcal disease. ACIP recommends a booster vaccine for the following scenarios:
HUMAN PAPILLOMAVIRUS VACCINE
9-valent human papillomavirus vaccine (9vHPV) is considered medically necessary and, therefore, covered for the following individuals:
Issued on - 08/22/2019